{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:10:37Z","timestamp":1779127837957,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glucocorticoids are an emerging component of the tumor microenvironment and play a multifaceted role in modulating immune responses. Adrenocortical carcinoma (ACC) is a rare endocrine malignancy characterized by systemic cortisol excess in ~\u200960% of cases. Responses to immune checkpoint inhibitors (ICI)\u00a0in patients with ACC are variable, and currently, no reliable biomarkers exist to predict therapeutic outcomes. Here,\n                    <jats:italic>in vitro-<\/jats:italic>\n                    differentiated and glucocorticoid-polarized peripheral blood monocytes from healthy donors were characterized using NanoString nCounter gene expression analysis, western blotting, and ELISA.\n                    <jats:italic>In vivo<\/jats:italic>\n                    , ACC-bearing mice were treated with immune checkpoint inhibitors and mifepristone. In human ACC tumor samples, immunohistochemistry was employed to quantify intratumoral macrophages, while mass spectrometry was applied to measure steroid hormone concentrations. We report that ACC tumors are highly infiltrated by CD68+\/CD163\u2009+\u2009macrophages, independent of cortisol overproduction.\n                    <jats:italic>In vitro<\/jats:italic>\n                    , glucocorticoid exposure polarized macrophages towards a C1Q+ CD163\u2009+\u2009subtype with enhanced phagocytic activity. Upon IFN\u03b3 stimulation, secretion of the T cell chemoattractant CXCL9 was higher in C1Q+ macrophages than in classical pro-inflammatory M1 macrophages. In ACC-bearing mice, treatment with immune checkpoint inhibitors and concurrent blockade of the glucocorticoid receptor with mifepristone reduced tumoral CXCL9 expression and CD4\u2009+\u2009T cell infiltration compared to ICI monotherapy. In ACC patient samples, intratumoral macrophage marker expression positively correlated with markers indicative of T cell infiltration and improved patient survival. Moreover, the percentage of macrophages detected by immunohistochemistry positively correlated with response to immunotherapy. Collectively, this study identifies a glucocorticoid-induced C1Q+ CD163\u2009+\u2009macrophage phenotype that may contribute to T cell recruitment and enhance the efficacy of immunotherapy in ACC.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-52733-y","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:37:37Z","timestamp":1779125857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucocorticoids induce a phagocytic C1Q+ macrophage phenotype primed for IFN\u03b3-dependent CXCL9 secretion"],"prefix":"10.1038","volume":"16","author":[{"given":"Alexandra S.","family":"Triebig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Maier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Schwarzlmueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sena","family":"Atici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin E.","family":"Kirmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasileios","family":"Chortis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kleiton S.","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Breault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Gottschlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura-Sophie","family":"Landwehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Bechmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirko","family":"Peitzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagarajan","family":"Paramasivam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Theurich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Fr\u00f6hling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanno","family":"Glimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"H\u00fcbschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Pedro","family":"Friedmann-Angeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Weigand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kroiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"3","key":"52733_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.immuni.2020.08.005","volume":"53","author":"N Acharya","year":"2020","unstructured":"Acharya, N. et al. Endogenous glucocorticoid signaling regulates CD8+ T cell differentiation and development of dysfunction in the tumor microenvironment. Immunity 53(3), 658-671.e6. https:\/\/doi.org\/10.1016\/j.immuni.2020.08.005 (2020).","journal-title":"Immunity"},{"issue":"21","key":"52733_CR2","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1038\/onc.2010.629","volume":"30","author":"D Sidler","year":"2011","unstructured":"Sidler, D. et al. Colon cancer cells produce immunoregulatory glucocorticoids. Oncogene 30(21), 2411\u20139. https:\/\/doi.org\/10.1038\/onc.2010.629 (2011).","journal-title":"Oncogene"},{"issue":"18","key":"52733_CR3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164599","volume":"133","author":"MD Taves","year":"2023","unstructured":"Taves, M. D. et al. Tumors produce glucocorticoids by metabolite recycling, not synthesis, and activate Tregs to promote growth. J. Clin. Invest. 133(18), e164599. https:\/\/doi.org\/10.1172\/JCI164599 (2023).","journal-title":"J. Clin. Invest."},{"issue":"5","key":"52733_CR4","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood-2005-07-2760","volume":"107","author":"N Cohen","year":"2006","unstructured":"Cohen, N. et al. GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. Blood 107(5), 2037\u201344. https:\/\/doi.org\/10.1182\/blood-2005-07-2760 (2006).","journal-title":"Blood"},{"issue":"1","key":"52733_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood-2006-10-052506","volume":"110","author":"H Hamdi","year":"2007","unstructured":"Hamdi, H. et al. Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper. Blood 110(1), 211\u20139. https:\/\/doi.org\/10.1182\/blood-2006-10-052506 (2007).","journal-title":"Blood"},{"issue":"11","key":"52733_CR6","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","volume":"49","author":"TMA Kerkhofs","year":"2013","unstructured":"Kerkhofs, T. M. A. et al. Adrenocortical carcinoma: A population-based study on incidence and survival in the Netherlands since 1993. Eur. J. Cancer 49(11), 2579\u201386. https:\/\/doi.org\/10.1016\/j.ejca.2013.02.034 (2013).","journal-title":"Eur. J. Cancer"},{"key":"52733_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2015.00045","volume":"3","author":"R Lib\u00e9","year":"2015","unstructured":"Lib\u00e9, R. Adrenocortical carcinoma (ACC): Diagnosis, prognosis, and treatment. Front. Cell Dev. Biol. 3, 45. https:\/\/doi.org\/10.3389\/fcell.2015.00045 (2015).","journal-title":"Front. Cell Dev. Biol."},{"issue":"23","key":"52733_CR8","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht, M. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366(23), 2189\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1200966 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"52733_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/cancers16050900","volume":"16","author":"O Ababneh","year":"2024","unstructured":"Ababneh, O. et al. The efficacy and safety of immune checkpoint inhibitors in adrenocortical carcinoma: A systematic review and meta-analysis. Cancers 16(5), 900. https:\/\/doi.org\/10.3390\/cancers16050900 (2024).","journal-title":"Cancers"},{"key":"52733_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4511","author":"Y Zhu","year":"2024","unstructured":"Zhu, Y., Cai, L. & Peng, X. Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4511 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"52733_CR11","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","volume":"164","author":"CD Mills","year":"2000","unstructured":"Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J. & Hill, A. M. M-1\/M-2 macrophages and the Th1\/Th2 paradigm. J. Immunol. 164(12), 6166\u201373. https:\/\/doi.org\/10.4049\/jimmunol.164.12.6166 (2000).","journal-title":"J. Immunol."},{"issue":"1","key":"52733_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","volume":"21","author":"J Liu","year":"2021","unstructured":"Liu, J., Geng, X., Hou, J. & Wu, G. New insights into M1\/M2 macrophages: Key modulators in cancer progression. Cancer Cell. Int. 21(1), 389. https:\/\/doi.org\/10.1186\/s12935-021-02089-2 (2021).","journal-title":"Cancer Cell. Int."},{"issue":"6","key":"52733_CR13","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2024.04.011","volume":"42","author":"MJ van Elsas","year":"2024","unstructured":"van Elsas, M. J. et al. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell 42(6), 1032-1050e.e10. https:\/\/doi.org\/10.1016\/j.ccell.2024.04.011 (2024).","journal-title":"Cancer Cell"},{"issue":"12","key":"52733_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1222","volume":"9","author":"G Sreejit","year":"2020","unstructured":"Sreejit, G., Fleetwood, A. J., Murphy, A. J. & Nagareddy, P. R. Origins and diversity of macrophages in health and disease. Clin. Transl. Immunol. 9(12), e1222. https:\/\/doi.org\/10.1002\/cti2.1222 (2020).","journal-title":"Clin. Transl. Immunol."},{"issue":"3","key":"52733_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/JLB.6A1120-744R","volume":"111","author":"CB Anders","year":"2022","unstructured":"Anders, C. B. et al. Use of integrated metabolomics, transcriptomics, and signal protein profile to characterize the effector function and associated metabotype of polarized macrophage phenotypes. J. Leukoc. Biol. 111(3), 667\u201393. https:\/\/doi.org\/10.1002\/JLB.6A1120-744R (2022).","journal-title":"J. Leukoc. Biol."},{"issue":"11","key":"52733_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21(11), 11. https:\/\/doi.org\/10.1038\/s41573-022-00520-5 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"52733_CR17","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.4049\/jimmunol.1200662","volume":"189","author":"G Zizzo","year":"2012","unstructured":"Zizzo, G., Hilliard, B. A., Monestier, M. & Cohen, P. L. Efficient clearance of early apoptotic cells by human macrophages requires \u201cM2c\u201d polarization and MerTK induction. J. Immunol. 189(7), 3508\u201320. https:\/\/doi.org\/10.4049\/jimmunol.1200662 (2012).","journal-title":"J. Immunol."},{"issue":"8010","key":"52733_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41586-024-07282-7","volume":"629","author":"JP Auger","year":"2024","unstructured":"Auger, J. P. et al. Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids. Nature 629(8010), 184\u201392. https:\/\/doi.org\/10.1038\/s41586-024-07282-7 (2024).","journal-title":"Nature"},{"issue":"11","key":"52733_CR19","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","volume":"11","author":"P Horak","year":"2021","unstructured":"Horak, P. et al. Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov. 11(11), 2780\u201395. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0126 (2021).","journal-title":"Cancer Discov."},{"issue":"8","key":"52733_CR20","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1210\/clinem\/dgaa293","volume":"105","author":"I Weigand","year":"2020","unstructured":"Weigand, I. et al. Expression of SOAT1 in adrenocortical carcinoma and response to Mitotane monotherapy: An ENSAT multicenter study. J. Clin. Endocrinol. Metab. 105(8), 2642\u201353. https:\/\/doi.org\/10.1210\/clinem\/dgaa293 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"52733_CR21","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1530\/EJE-20-1423","volume":"184","author":"LS Landwehr","year":"2021","unstructured":"Landwehr, L. S. et al. A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden. Eur. J. Endocrinol. 184(6), 823\u201335. https:\/\/doi.org\/10.1530\/EJE-20-1423 (2021).","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"52733_CR22","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1055\/a-1440-0278","volume":"53","author":"N Bechmann","year":"2021","unstructured":"Bechmann, N. et al. Adrenal hormone interactions and metabolism: A single sample multi-omics approach. Horm. Metab. Res. 53(5), 326\u201334. https:\/\/doi.org\/10.1055\/a-1440-0278 (2021).","journal-title":"Horm. Metab. Res."},{"key":"52733_CR23","unstructured":"FlowJo \u2122 Software (for Windows) Version v10.8. Ashland, OR: Becton, Dickinson and Company; (2023)."},{"issue":"30","key":"52733_CR24","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.1038\/s41388-020-1358-5","volume":"39","author":"KS Borges","year":"2020","unstructured":"Borges, K. S. et al. Wnt\/\u03b2-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice. Oncogene 39(30), 5282\u201391. https:\/\/doi.org\/10.1038\/s41388-020-1358-5 (2020).","journal-title":"Oncogene"},{"issue":"13","key":"52733_CR25","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1158\/0008-5472.CAN-22-2712","volume":"83","author":"DR Mohan","year":"2023","unstructured":"Mohan, D. R. et al. \u03b2-Catenin-driven differentiation is a tissue-specific epigenetic vulnerability in adrenal cancer. Cancer Res. 83(13), 2123\u201341. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-2712 (2023).","journal-title":"Cancer Res."},{"issue":"3","key":"52733_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2385-4","volume":"11","author":"I Weigand","year":"2020","unstructured":"Weigand, I. et al. Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. Cell Death Dis. 11(3), 3. https:\/\/doi.org\/10.1038\/s41419-020-2385-4 (2020).","journal-title":"Cell Death Dis."},{"issue":"4","key":"52733_CR27","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.4049\/jimmunol.180.4.2329","volume":"180","author":"H Pa\u00efdassi","year":"2008","unstructured":"Pa\u00efdassi, H. et al. C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J Immunol 180(4), 2329. https:\/\/doi.org\/10.4049\/jimmunol.180.4.2329 (2008).","journal-title":"J Immunol"},{"issue":"5","key":"52733_CR28","doi-asserted-by":"publisher","first-page":"e1264","DOI":"10.1038\/cddis.2014.210","volume":"5","author":"YY Liang","year":"2014","unstructured":"Liang, Y. Y. et al. Serum-dependent processing of late apoptotic cells for enhanced efferocytosis. Cell. Death Dis. 5 (5), e1264\u2013e1264. https:\/\/doi.org\/10.1038\/cddis.2014.210 (2014).","journal-title":"Cell. Death Dis."},{"key":"52733_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga, R. et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat. Rev. 63, 40\u201347 (2018). PubMed PMID: 29207310; PubMed Central PMCID: PMC5801162.","journal-title":"Cancer Treat. Rev."},{"key":"52733_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1161768","volume":"14","author":"S Khadka","year":"2023","unstructured":"Khadka, S., Druffner, S. R., Duncan, B. C. & Busada, J. T. Glucocorticoid regulation of cancer development and progression. Front Endocrinol 14, 1161768. https:\/\/doi.org\/10.3389\/fendo.2023.1161768 (2023).","journal-title":"Front Endocrinol"},{"issue":"6","key":"52733_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41574-025-01102-2","volume":"21","author":"P Schwarzlmueller","year":"2025","unstructured":"Schwarzlmueller, P. et al. Steroid hormones as modulators of anti-tumoural immunity. Nat Rev Endocrinol 21(6), 331\u201343. https:\/\/doi.org\/10.1038\/s41574-025-01102-2 (2025).","journal-title":"Nat Rev Endocrinol"},{"issue":"5795","key":"52733_CR32","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960\u20134. https:\/\/doi.org\/10.1126\/science.1129139 (2006).","journal-title":"Science"},{"issue":"4","key":"52733_CR33","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman, W. H., Pag\u00e8s, F., Saut\u00e8s-Fridman, C. & Galon, J. The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 12(4), 298\u2013306. https:\/\/doi.org\/10.1038\/nrc3245 (2012).","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"52733_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3), 203\u201313. https:\/\/doi.org\/10.1056\/NEJMoa020177 (2003).","journal-title":"N Engl J Med"},{"issue":"1","key":"52733_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000469","volume":"8","author":"LS Landwehr","year":"2020","unstructured":"Landwehr, L. S. et al. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J. Immunother. Cancer 8(1), e000469. https:\/\/doi.org\/10.1136\/jitc-2019-000469 (2020).","journal-title":"J. Immunother. Cancer"},{"issue":"21","key":"52733_CR36","doi-asserted-by":"publisher","first-page":"10061","DOI":"10.1111\/jcmm.16936","volume":"25","author":"JJ Baechle","year":"2021","unstructured":"Baechle, J. J. et al. Integrative computational immunogenomic profiling of cortisol-secreting adrenocortical carcinoma. J. Cell Mol. Med. 25(21), 10061\u201372. https:\/\/doi.org\/10.1111\/jcmm.16936 (2021).","journal-title":"J. Cell Mol. Med."},{"issue":"6","key":"52733_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/ejendo\/lvad054","volume":"188","author":"H Remde","year":"2023","unstructured":"Remde, H. et al. Outcome of immunotherapy in adrenocortical carcinoma: A retrospective cohort study. Eur. J. Endocrinol. 188(6), 485\u201393. https:\/\/doi.org\/10.1093\/ejendo\/lvad054 (2023).","journal-title":"Eur. J. Endocrinol."},{"issue":"31","key":"52733_CR38","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1038\/s41388-021-01897-0","volume":"40","author":"Z Xiang","year":"2021","unstructured":"Xiang, Z. et al. Dexamethasone suppresses immune evasion by inducing GR\/STAT3 mediated downregulation of PD-L1 and IDO1 pathways. Oncogene 40 (31), 5002\u20135012. https:\/\/doi.org\/10.1038\/s41388-021-01897-0 (2021). PubMed PMID: 34175886; PubMed Central PMCID: PMC8235907.","journal-title":"Oncogene"},{"key":"52733_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01731","author":"K Wu","year":"2020","unstructured":"Wu, K. et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.01731 (2020).","journal-title":"Front. Immunol."},{"key":"52733_CR40","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/1471-2407-12-306","volume":"12","author":"C Medrek","year":"2012","unstructured":"Medrek, C., Pont\u00e9n, F., Jirstr\u00f6m, K. & Leandersson, K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC. Cancer 12, 306. https:\/\/doi.org\/10.1186\/1471-2407-12-306 (2012).","journal-title":"BMC. Cancer"},{"issue":"4","key":"52733_CR41","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4132\/jptm.2015.06.01","volume":"49","author":"KY Jung","year":"2015","unstructured":"Jung, K. Y. et al. Cancers with higher density of tumor-associated macrophages were associated with poor survival rates. J. Pathol. Transl. Med. 49(4), 318\u201324. https:\/\/doi.org\/10.4132\/jptm.2015.06.01 (2015).","journal-title":"J. Pathol. Transl. Med."},{"issue":"41","key":"52733_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add0422","volume":"8","author":"JJ Wilmouth","year":"2022","unstructured":"Wilmouth, J. J. et al. Sexually dimorphic activation of innate antitumor immunity prevents adrenocortical carcinoma development. Sci. Adv. 8(41), eadd0422. https:\/\/doi.org\/10.1126\/sciadv.add0422 (2022).","journal-title":"Sci. Adv."},{"key":"52733_CR43","doi-asserted-by":"publisher","first-page":"1033497","DOI":"10.3389\/fimmu.2023.1033497","volume":"14","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. The immune-metabolic crosstalk between CD3\u2009+\u2009C1q\u2009+\u2009TAM and CD8\u2009+\u2009T cells associated with relapse-free survival in HCC. Front. Immunol. 14, 1033497. https:\/\/doi.org\/10.3389\/fimmu.2023.1033497 (2023). PubMed PMID: 36845133; PubMed Central PMCID: PMC9948089.","journal-title":"Front. Immunol."},{"issue":"1","key":"52733_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10346","volume":"7","author":"R Bulla","year":"2016","unstructured":"Bulla, R. et al. C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat. Commun. 7(1), 10346. https:\/\/doi.org\/10.1038\/ncomms10346 (2016).","journal-title":"Nat. Commun."},{"issue":"7","key":"52733_CR45","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.trecan.2022.02.006","volume":"8","author":"M Revel","year":"2022","unstructured":"Revel, M., Saut\u00e8s-Fridman, C., Fridman, W. H. & Roumenina, L. T. C1q+ macrophages: Passengers or drivers of cancer progression. Trends Cancer 8(7), 517\u201326. https:\/\/doi.org\/10.1016\/j.trecan.2022.02.006 (2022).","journal-title":"Trends Cancer"},{"key":"52733_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101420","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer. Cell Rep. Med. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101420 (2024).","journal-title":"Cell Rep. Med."},{"issue":"7","key":"52733_CR47","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","volume":"185","author":"R Nalio Ramos","year":"2022","unstructured":"Nalio Ramos, R. et al. Tissue-resident FOLR2\u2009+\u2009macrophages associate with CD8\u2009+\u2009T cell infiltration in human breast cancer. Cell 185(7), 1189-1207e.e25. https:\/\/doi.org\/10.1016\/j.cell.2022.02.021 (2022).","journal-title":"Cell"},{"issue":"7","key":"52733_CR48","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1158\/2326-6066.CIR-18-0891","volume":"7","author":"LT Roumenina","year":"2019","unstructured":"Roumenina, L. T. et al. Tumor cells hijack macrophage-produced complement C1q to promote tumor growth. Cancer Immunol. Res. 7(7), 1091\u2013105. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0891 (2019).","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"52733_CR49","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1042\/EBC20230001","volume":"67","author":"CW Wong","year":"2023","unstructured":"Wong, C. W., Huang, Y. Y. & Hurlstone, A. The role of IFN-\u03b3-signalling in response to immune checkpoint blockade therapy. Essays Biochem. 67(6), 991\u20131002. https:\/\/doi.org\/10.1042\/EBC20230001 (2023).","journal-title":"Essays Biochem."},{"issue":"6","key":"52733_CR50","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","volume":"50","author":"MT Chow","year":"2019","unstructured":"Chow, M. T. et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity 50(6), 1498-1512e5. https:\/\/doi.org\/10.1016\/j.immuni.2019.04.010 (2019).","journal-title":"Immunity"},{"issue":"4","key":"52733_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101479","volume":"5","author":"RJ Lim","year":"2024","unstructured":"Lim, R. J. et al. CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. Cell Rep. Med. 5(4), 101479. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101479 (2024).","journal-title":"Cell Rep. Med."},{"issue":"2","key":"52733_CR52","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House, I. G. et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res Off J Am Assoc Cancer Res 26(2), 487\u2013504. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1868 (2020).","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"52733_CR53","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2147\/JHC.S450468","volume":"11","author":"P Wang","year":"2024","unstructured":"Wang, P. et al. CXCL9 Overexpression Predicts Better HCC Response to Anti-PD-1 Therapy and Promotes N1 Polarization of Neutrophils. J. Hepatocell Carcinoma. 11, 787\u2013800. https:\/\/doi.org\/10.2147\/JHC.S450468 (2024).","journal-title":"J. Hepatocell Carcinoma"},{"issue":"3","key":"52733_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.471","volume":"5","author":"Y Yu","year":"2024","unstructured":"Yu, Y. et al. Unraveling the role of M1 macrophage and CXCL9 in predicting immune checkpoint inhibitor efficacy through multicohort analysis and single-cell RNA sequencing. MedComm 5(3), e471. https:\/\/doi.org\/10.1002\/mco2.471 (2024).","journal-title":"MedComm"},{"issue":"6657","key":"52733_CR55","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1126\/science.ade2292","volume":"381","author":"R Bill","year":"2023","unstructured":"Bill, R. et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science 381(6657), 515\u201324. https:\/\/doi.org\/10.1126\/science.ade2292 (2023).","journal-title":"Science"},{"issue":"10","key":"52733_CR56","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol. 16(10), 626\u201338. https:\/\/doi.org\/10.1038\/nri.2016.90 (2016).","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"52733_CR57","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s43587-023-00420-2","volume":"3","author":"KM Warde","year":"2023","unstructured":"Warde, K. M. et al. Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner. Nat. Aging 3(7), 846\u201365. https:\/\/doi.org\/10.1038\/s43587-023-00420-2 (2023).","journal-title":"Nat. Aging"},{"issue":"1","key":"52733_CR58","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s00423-024-03507-5","volume":"409","author":"C Nastos","year":"2024","unstructured":"Nastos, C. et al. The impact of adrenocortical carcinoma hormone secreting status as a predictor of poor survival: A systematic review and meta-analysis. Langenbecks Arch Surg. 409(1), 316. https:\/\/doi.org\/10.1007\/s00423-024-03507-5 (2024).","journal-title":"Langenbecks Arch Surg."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52733-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52733-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52733-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:52:37Z","timestamp":1779126757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52733-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52733"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52733-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The ENSAT study has been approved by the ethics committees of the Ludwig-Maximilians-University, Munich, Germany (approval number: 379\/10) and the Julius-Maximilians-University W\u00fcrzburg (approval number: 88\/11). All animal procedures were approved by the Institutional Animal Care and Use Committee of Boston Children\u2019s Hospital. For the use of data from a public database, an approval exemption has been obtained from the LMUs\u00b4 ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"15345"}}